Ranger Investment Management L.P. Decreases Holdings in Repligen Co. (NASDAQ:RGEN)

Ranger Investment Management L.P. lowered its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 1.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 226,067 shares of the biotechnology company's stock after selling 4,324 shares during the period. Repligen makes up 2.1% of Ranger Investment Management L.P.'s investment portfolio, making the stock its 15th largest position. Ranger Investment Management L.P. owned about 0.40% of Repligen worth $32,540,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Signaturefd LLC raised its position in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in Repligen during the fourth quarter worth about $29,000. Resources Management Corp CT ADV purchased a new position in shares of Repligen in the 3rd quarter worth about $37,000. Quarry LP lifted its position in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after buying an additional 239 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after buying an additional 110 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Performance

RGEN traded up $2.27 on Monday, reaching $125.13. 193,439 shares of the stock were exchanged, compared to its average volume of 700,051. The company's 50-day moving average price is $143.12 and its 200 day moving average price is $146.32. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market capitalization of $7.03 billion, a PE ratio of -245.35, a PEG ratio of 4.54 and a beta of 1.27. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. As a group, sell-side analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax acquired 250 shares of the business's stock in a transaction on Monday, March 17th. The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of analyst reports. HC Wainwright reiterated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Evercore ISI initiated coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective on the stock. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday, April 4th. TD Cowen started coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price target on the stock. Finally, Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and a consensus price target of $178.64.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.